Accelerating Medicines Partnership® Program
The goal of the Accelerating Medicines Partnership® (AMP®) program is to bring together the resources of the National Institutes of Health (NIH) and the private sector to improve our understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate therapies to patients.
A Model for Public-Private Partnerships
The goal of the Accelerating Medicines Partnership® (AMP®) program is to bring together the resources of NIH and the private sector to improve our understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate therapies to patients. Launched in 2014, the program is currently comprised of seven active projects and is currently supported by 16 NIH Institutes, Centers, and cross-institute initiatives, 31 industry partners, and 28 non-profit partners, with additional advisory participation by the US Food and Drug Administration and the European Medicines Agency.
Read more about the AMP program on the National Institutes of Health website.
Focus on Pre-Competitive Advancements, Public Access, and Improving Patient Outcomes
As a non-profit organization supporting the mission of the NIH, the Foundation for the National Institutes of Health manages the AMP program with the interests of the collective scientific and medical research communities in mind. All AMP projects operate under the broad principle of delivering pre-competitive advancements to the research and medical fields and enabling the broadest possible access and use of AMP research discoveries.
A critical component of each public-private partnership in the AMP program is an agreement among partners to make data and analyses arising from the collaboration publicly accessible to benefit the broader biomedical community. Individual AMP projects frequently establish public portals to rapidly disseminate data from their research efforts, and AMP-funded publications are required to be made available publicly within specific timeframes.
At the center of the AMP program is a common goal of accelerating new and effective therapies to patients. AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes.
Current Industry and Non-Profit Partners
- Aligning Science Across Parkinson’s (ASAP) Initiative*
- Alliance for Regenerative Medicine (ARM)*
- Alzheimer’s Association®*
- American Heart Association
- American Psychiatric Association Foundation*
- American Society of Echocardiography*
- American Society of Gene & Cell Therapy*
- The Arthritis Foundation, Inc.*
- ASC Therapeutics Inc*
- Bayer US*
- Biogen Inc.*
- Boehringer Ingelheim*
- Bristol Myers Squibb*
- California Institute for Regenerative Medicine (CIRM)
- Cytokinetics, Incorporated*
- Danaher Corporation*
- Eisai Inc.*
- Eli Lilly and Company*
- Foundation Fighting Blindness*
- Gates Ventures*
- Genetic Alliance
- Ionis Pharmaceuticals, Inc.*
- Janssen Research & Development, LLC*
- Lupus Foundation of America*
- Lupus Research Alliance*
- Merck Sharp & Dohme LLC*
- The Michael J. Fox Foundation for Parkinson’s Research (MJFF)*
- National Alliance on Mental Illness*
- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)*
- National Organization for Rare Disorders (NORD)*
- National Psoriasis Foundation*
- Novartis Institutes for BioMedical Research*
- Novartis Pharma AG*
- Novo Nordisk*
- One Mind*
- Otsuka Pharmaceutical Development & Commercialization, Inc.*
- Ovid Therapeutics Inc.*
- Pfizer Inc.*
- REGENXBIO Inc.*
- Rett Syndrome Research Trust*
- Rheumatology Research Foundation*
- RTW Charitable Foundation*
- Schizophrenia & Psychosis Action Alliance*
- Sjögren’s Foundation*
- Spark Therapeutics*
- Takeda Pharmaceutical Company Limited*
- Taysha Gene Therapies*
- Thermo Fisher Scientific*
- Ultragenyx Pharmaceutical*
- Ultromics, Inc.*
*Provided financial or in-kind support for this program.
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.